Lyell Immunopharma Inc (LYEL)
2.17
-0.08
(-3.56%)
USD |
NASDAQ |
Apr 30, 16:00
2.17
0.00 (0.00%)
Pre-Market: 20:00
Lyell Immunopharma Shareholders Equity (Quarterly): 654.95M for Dec. 31, 2023
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 654.95M |
| September 30, 2023 | 697.57M |
| June 30, 2023 | 736.86M |
| March 31, 2023 | 783.83M |
| December 31, 2022 | 833.25M |
| September 30, 2022 | 820.03M |
| June 30, 2022 | 868.04M |
| Date | Value |
|---|---|
| March 31, 2022 | 881.25M |
| December 31, 2021 | 929.79M |
| September 30, 2021 | 986.47M |
| June 30, 2021 | 1.022B |
| March 31, 2021 | 676.92M |
| December 31, 2020 | 718.44M |
Shareholders' Equity Definition
Shareholder's Equity is a main portion of the balance sheet of a company that measures the net value of a company. The reason for this is because the from an accounting perspective, the balance sheet equation is Shareholder's Equity = Assets - Liabilities. A few examples of shareholder's equity of a company include retained earnings, paid in capital, and preferred stock.
Shareholders Equity (Quarterly) Range, Past 5 Years
654.95M
Minimum
Dec 2023
1.022B
Maximum
Jun 2021
816.10M
Average
820.03M
Median
Sep 2022
Shareholders Equity (Quarterly) Benchmarks
| GlycoMimetics Inc | 38.41M |
| Candel Therapeutics Inc | 12.74M |
| Eliem Therapeutics Inc | 107.60M |
| Entrada Therapeutics Inc | 242.36M |
| NovaBay Pharmaceuticals Inc | 3.314M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 750.03M |
| Total Liabilities (Quarterly) | 95.08M |
| Current Ratio | 16.07 |